CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 92 enrolled
Drug / intervention
Prazosin medication +1 moredrug
Likely dose
Prazosin medication 0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00762710
NCT00762710Phase 2Completed
CompareCT.gov

Clinical Trial of the Adrenergic Alpha-1 Antagonist Prazosin for Alcohol Dependence

Seattle Institute for Biomedical and Clinical Research·interventional·Posted Sep 30, 2008·Updated Jun 4, 2020

In Brief

A Phase 2 clinical trial evaluating Prazosin medication and Placebo medication for Alcoholism. Completed, enrolled 92 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether the drug prazosin is effective for the treatment of alcohol dependency.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcoholism
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA), VA Puget Sound Health Care System, University of Washington

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 30, 2008
Enrollment StartJan 1, 2008
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 17.8 years ago

Interventions

Prazosin medicationdrug

Form: Prazosin will be taken orally, in the form of pills. Dosing: 9 AM, 3 PM, 9 PM Days 1-2: 0 mg, 0 mg, 1 mg Days 3-4: 1 mg, 1 mg, 1 mg Days 5-7: 2 mg, 2 mg, 2 mg Day 8-10: 2 mg, 2 mg, 6 mg Day 11-14: 4 mg, 4 mg, 6 mg Day 15-84: 4 mg, 4 mg, 8 mg

Placebo medicationdrug

Form: Placebo will be taken orally, in the form of pills. Dosing: 9 AM, 3 PM, 9 PM Days 1-2: 0 mg, 0 mg, 1 mg Days 3-4: 1 mg, 1 mg, 1 mg Days 5-7: 2 mg, 2 mg, 2 mg Day 8-10: 2 mg, 2 mg, 6 mg Day 11-14: 4 mg, 4 mg, 6 mg Day 15-84: 4 mg, 4 mg, 8 mg